Liftstream is an executive search recruitment company in the life sciences sector
Jazz Pharmaceuticals to acquire rare disease company Gentium
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Acute Lymphoblastic Leukemia, ALL, Azur Pharma, Bruce Cozadd, Defitelio, Dublin, EMA, Erwinase, EU, EUSA Pharma, FDA, Gentium, Graft vs Host Disease, GvHD, Ireland, Italy, Jazz Pharmaceuticals, Khalid Islam, M&A, Orphan drugs, Rare Disease, regulatory approval, severe hepatic veno-occlusive disease, VOD
2 Comments
Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged acquisition, Basingstoke, Cinryze, clinical development, EU, Flemming Ornskov, Geneva, immune disorder hereditary angioedema, Lotus Tissue Repair, marketed products, Pipeline, regulatory approval, restructure, SARcode, Shire, Shire HGT, Shire Rare Disease, Switzerland, USA, Viropharma, Zug
Leave a comment
Endocyte diagnoses companion in Merck to set precedent!
Authored by Karl Simpson
Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged BioRN, cancer, companion diagnostics, diagnostics, ECo652, EMA, Endocyte, etarfolatide, EU, European Commission, FDA, folate-receptor positive, IND, Merck, non-small cell lung cancer, oncology, Orphan Drug Congress, ovarian cancer, PRECEDENT, PROCEED, PSMA, Ron Ellis, small-molecule drug conjugates, vintafolide, viral infections
Leave a comment
Medical Device Industry Engineering Emerging Markets Future
Authored by James Sheppard
Posted in Medical Device
Tagged Alpha X-Ray Technologies, Brazil, BRIC, china, China Bord Blood, Covidien, Essex Woodland, EU, GE Healthcare, India, Indonesia, Investment, J&J, Japan, Johnson & Johnson, Kanghui Holdings, LifeTech Scientific Corp, Medical Device, Meditronics, Medtronic, Microport, N-11, Omar Ishrak, Philips Healthcare, Ronald De Jong, Russia, Shanghai, Taiwan, us, Venezuela, venture capital
Leave a comment